Early preclinical studies showed that the combination of SST2- and SST5-preferential agonists can act synergistically in the inhibition of GH secretion in both GHRH-stimulated human fetal pituitary cells, as well as in somatomammotroph pituitary tumor cells [9,42]. Here, GHRH is linked to pituitary tumor.